Obinutuzumab for first episode of minimal change disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if obinutuzumab, a targeted therapy, can safely and effectively treat adults with their first episode of minimal change disease (MCD), a kidney condition causing protein leakage. Participants will receive the drug to see if it reduces protein in urine and improves symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with nephrotic syndrome (low albumin and high protein in urine) caused by a first occurrence of minimal change disease
- Your MCD diagnosis is confirmed by a kidney biopsy
- You are not pregnant or breastfeeding, and agree to use contraception if applicable
- You do not have a recent infection like hepatitis B, C, or HIV
- You have not had certain prior treatments like B cell therapies or cyclophosphamide recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injected drug called BAT4406F for people with Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS), two types of kidney diseases that cause swelling and high protein in urine. It aims to see if the drug can help patients who have responded well to steroid therapy in the past.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests a new drug called obinutuzumab for adults whose nephrotic syndrome (a kidney disease causing swelling and protein in urine) has relapsed after stopping rituximab. It aims to see if obinutuzumab can help prevent future relapses.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Hear when a new Minimal Change Disease (MCD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.